Uterine Cancer Diagnosis: A Comprehensive Overview

Department of Neurosurgery, University of SMK Science and Technology, Iraq

Uterine cancer, primarily encompassing endometrial carcinoma and uterine sarcoma, represents a significant health concern for women worldwide. This comprehensive overview delves into the current methodologies and advancements in the diagnosis of uterine cancer, highlighting the importance of early detection in improving patient outcomes. The abstract covers various diagnostic modalities, including imaging techniques such as transvaginal ultrasound, hysteroscopy, and magnetic resonance imaging (MRI), as well as the role of endometrial biopsy and curettage in confirming the diagnosis. The review also discusses emerging biomarkers and genetic testing, which offer potential for personalized medicine approaches. The integration of these diagnostic tools with clinical decision-making processes is essential for accurate staging and treatment planning. By evaluating recent advancements and comparing diagnostic accuracy, the overview aims to provide a thorough understanding of the diagnostic landscape of uterine cancer, addressing challenges and future directions in the field.

Uterine cancer, encompassing endometrial cancer and uterine sarcomas, represents a significant concern in gynaecologic oncology due to its rising incidence and diverse clinical presentations. This comprehensive overview delves into the multifaceted aspects of uterine cancer diagnosis, providing an in-depth analysis of current methodologies, advancements, and challenges. The diagnostic approach begins with a thorough patient history and

Murshid Imam, Department of Neurosurgery, University of SMK Science and Technology, Iraq, E-mail: ima-.murshid@gmail.com

01-July-2024, Manuscript No: jcd-24-144370; 03-July-2024, PreQC No. jcd-24-144370 (PQ); 17-July-2024, QC No. jcd-24-144370; 24-July-2024, Manuscript No. jcd-24-144370 (R); 30-July-2024, DOI: 10.4172/2476-2253.1000245

Murshid I (2024) Uterine Cancer Diagnosis: A Comprehensive Overview. J Cancer Diagn 8: 245.

© 2024 Murshid I. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

[illegible] [9].

[illegible] [10].

R[illegible]

[illegible]

A[illegible]: M[illegible] 50.

O[illegible]: E[illegible]

H[illegible]: C[illegible] (PCOS) [illegible]

F[illegible]: A[illegible]

R[illegible]: W[illegible]

S[illegible]:

- Ab[illegible]
- P[illegible]
- Pa[illegible]
- Ab[illegible]

D[illegible]

M[illegible]

[illegible]

I[illegible]

[illegible]

C[illegible] (C[illegible]): A CT [illegible]

M[illegible] (MRI): MRI [illegible]

E[illegible]

[illegible]

D&C ([illegible])

[illegible] -1.2 T[illegible]

[illegible]

1. Ugai T, Sasamoto N, Ando HM, Song M, Tamimi RM, et al. (2022) Is early-onset cancer an emerging global epidemic? Current evidence and future implications. Nature Reviews Clinical Oncology 19:656-673.

2. Ryndock EJ, Meyers C (2014) A risk for non-sexual transmission of human papillomavirus? Expert Rev. Anti Infect Ther 12: 1165-1170.

3. Petca A, Borislavschi A, Zvanca ME, Petca R, Sandru F, et al. (2020) Non-sexual HPV transmission and role of vaccination for a better future (Review). Exp Ther Med 20: 186.

4. Castle PE, Maza M (2016) Prophylactic HPV vaccination: Past, present, and future. Epidemiol Infect 144: 449-468.

5. Park IU, Introcaso C, Dunne EF (2015) Human papillomavirus and genital warts: A review of the evidence for the 2015 centers for disease control and prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis 61: 849-855.

6. Boda D, Docea AO, Calina D, Ilie MA, Caruntu C, et al. (2018) Human papilloma virus: Apprehending the link with carcinogenesis and unveiling new research avenues (Review). Int J Oncol 52: 637-655.

7. You W, Li S, Du r, Zheng J, Shen A (2018) Epidemiological study of high-risk human papillomavirus infection in subjects with abnormal cytological fndings in cervical cancer screening. Exp Ther Med 15: 412-418.

8. Chesson HWDUSasaĄya